USTR's Czech talks extend beyond Medicaid's MFN country basket. Medicare includes Czech prices, but company waivers and different formulas limit their reach.
USTR has raised pharmaceutical-pricing concerns with and the , but the two countries occupy different positions in U.S. MFN drug pricing. Italy is in the . The Czech Republic is outside it. Medicare's finalized , subject to a narrower set of drugs and a waiver that can remove a manufacturer's mandatory participation for the relevant quarter.
For pharmaceutical trade counsel, a European promise to pay more cannot be valued until the relevant U.S. program and company agreement are identified. The concession assessment needs to establish which American rebate calculation can use the affected price.
The distinction matters as Washington pursues Germany's Section 301 investigation. USTR's October 28 and 29 readouts establish concerns about Italian reimbursement and Czech pricing practices. Neither announces a pricing commitment or a new Section 301 investigation in those countries.
The Same Concession Enters Different Country Baskets
The GENEROUS manufacturer application document uses eight reference countries. Germany and Italy qualify. Czech prices do not directly enter that published basket. The model translates qualifying international prices into supplemental Medicaid rebates through agreements with participating manufacturers and states.
GLOBE uses 19 reference countries, including all three. Its inclusion of the Czech Republic creates a possible Medicare channel for a Czech concession that the published GENEROUS design lacks. Inclusion establishes where qualifying price data can come from. It does not establish that a particular manufacturer's drug is covered or that the country's price determines the U.S. result.
European Pricing Concessions and U.S. Reference-Country Coverage
Country membership as of November 13, 2026, under the published GENEROUS design and final GLOBE rule. These entries identify potential data sources. Manufacturer and drug eligibility, applicable waivers and the benchmark formula determine whether a price change affects a rebate.
Country
GENEROUS, Medicaid
GLOBE, Medicare Part B
Germany
Included
Included
Italy
Included
Included
Czech Republic
Not included
Included
The country distinction also limits what a German cost estimate can establish. Thomas Hwang's November 10 preprint models a 25 percent German price increase as reducing projected net Medicaid MFN savings by 3.8 percent, about $300 million annually against its MFN baseline. The German statutory insurers association GKV funded the work. It uses 2025 data, remains under peer review and excludes dynamic responses. That result cannot be carried across to Czech negotiations, whose prices are outside the published Medicaid basket.
A GENEROUS Agreement Can Remove a GLOBE Obligation
Before calculating a GLOBE price effect, counsel should open the manufacturer's GENEROUS participation agreement. In the GLOBE final-rule discussion of overlapping models, CMS says it intends to waive mandatory GLOBE participation for a manufacturer participating in GENEROUS during the relevant quarter, as necessary for the GENEROUS test. The waiver is to be implemented under that voluntary model's authority. The GENEROUS application document places such waivers in participation agreements.
A general MFN pledge or press announcement is therefore insufficient evidence of a waiver. Its terms and covered quarter matter. If the waiver applies, adding a higher Czech price to a GLOBE spreadsheet would model an obligation that the company does not have for that period.
For manufacturers still subject to GLOBE, drug eligibility imposes a further limit. The model covers qualifying single-source drugs and sole-source biological products in specified Part B categories, with an initial threshold of more than $100 million in Original Medicare Part B allowed charges over the specified 12-month measurement period. Exclusions include drugs with an effective Medicare maximum fair price and orphan-only drugs. The model's coinsurance adjustment also reaches a selected geographic cohort, rather than every Medicare patient. A national reimbursement agreement cannot be treated as a uniform change in American drug spending.
Under Method I, CMS identifies the lowest adjusted country-level price from available data. That benchmark generally remains in place, subject to the rule's provisions for late availability and data updates. A new European price announcement does not automatically reset it.
Method II instead uses complete, accepted manufacturer submissions to calculate a cross-country, volume-weighted average adjusted net price for the applicable quarter. CMS selects the higher available Method I or Method II benchmark. A Czech price therefore need not be the lowest to enter the Method II calculation. Its effect depends on the qualifying sales, their weight and which method supplies the selected benchmark. The rule then applies additional adjustments before calculating the rebate amount. The existing inflation-rebate calculation can still set the rebate, even when the international benchmark changes.
This changes the evidence counsel should request from the pricing team. A statement that a country is too expensive to set the lowest price may address Method I and still leave Method II unanswered. The assessment needs both calculations where data are available, along with the manufacturer's participation status.
A concession implemented during the current quarter could consequently enter that first submission if it changes qualifying transactions. An agreement announced now but implemented later would have a different reporting consequence. For GENEROUS, counsel should use the actual participation and state rebate agreements, since CMS allows states to select drugs and the application document warns that final negotiated terms may differ.
The immediate task is to attach the applicable agreement, covered drug and price period to each proposed concession before assigning it a U.S. savings effect. Reopen that assessment when a pricing commitment takes effect, CMS confirms the applicable waiver, accepted data change the selected benchmark or a court order alters the model's schedule.
Daily Trade Brief
Get the next one in your inbox.
New U.S. trade actions and the analysis that changes an import, customs, or counsel file, on weekday mornings after you confirm your address.
From reading to review
Run the numbers on your lane.
The duty calculator runs the current stack for any HTS code and origin. A free account opens full tool output, AD/CVD detail, Chapter 98 processing, and available exports.